R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24 [0.03%]
一石二鸟：现实世界数据在HTA和 reimbursemengt 中的作用之二十四篇：现状综述
Paul Arora,Sreeram V Ramagopalan
Paul Arora
In this update, we review a new bias appraisal tool, explore lessons from a trial emulation study, and describe the development of real-world evidence guidance in the Philippines. ...
Sieving for gold: external comparator studies to prioritize drugs for late-stage clinical trial [0.03%]
筛选黄金：外部比较研究优先选择药物进行临床试验
Samuel Vennin,Will Sopwith,Emiliano Calvo et al.
Samuel Vennin et al.
External comparator (EC) studies can improve identification of compounds with the most promising performance in pre-pivotal single-arm trials (SAT). As SAT output lacks comparative insights, EC studies allow efficient contextualization of c...
Acthar Gel versus standard of care for adults with proteinuria in nephrotic syndrome due to focal segmental glomerulosclerosis: cost-per-response analysis from the US healthcare perspective [0.03%]
阿克泰凝胶与标准疗法治疗由于局灶节段性肾小球硬化导致的成人肾病综合征蛋白尿的成本效益分析：从美国医疗保健行业的角度看
Jas Bindra,Ishveen Chopra,Kyle Hayes et al.
Jas Bindra et al.
Aim: Proteinuria poses a significant challenge in focal segmental glomerulosclerosis (FSGS), particularly when resistant to standard treatments. Acthar® Gel, a Food and Drug Administration (FDA)-approved treatment, may be a potential optio...
Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer [0.03%]
曲妥珠单抗经治HER2阳性转移性结直肠癌患者中tucatinib联合曲妥珠单抗的间接对比分析
Claire Watkins,Cyndy Simon,Peter Martin et al.
Claire Watkins et al.
Aim: In the single-arm MOUNTAINEER trial (NCT03043313) tucatinib in combination with trastuzumab showed an objective response rate (ORR) of 39.3% in patients with previously treated, HER2+ unresectable or metastatic colorectal cancer (mCRC)...
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis [0.03%]
抗环瓜氨酸肽抗体和类风湿因子阳性的类风湿关节炎患者接受英夫利昔α或阿巴西普一线治疗的疗效：队列研究数据及网络 meta分析
Gordon Lam,Hanke Zheng,Andrew Klink et al.
Gordon Lam et al.
Aim: To compare characteristics of patients with anticitrullinated protein antibody-positive (ACPA+) and rheumatoid factor-positive (RF+) rheumatoid arthritis (RA) who initiated abatacept or a tumor necrosis factor inhibitor (TNFi) as a fir...
Reshaping the cardiovascular continuum in the management of arterial and venous cardiovascular disease: a narrative review [0.03%]
动脉和静脉心血管疾病的管理中连续体的重塑：综述性文章
Khadija Hafidh,Melina Vega de Ceniga,Leonardo De Luca et al.
Khadija Hafidh et al.
The prevalence of cardiovascular disease (CVaD) is expected to double in the next 25 years, fueled by increasing prevalence of diabetes mellitus, obesity and hypertension. Cardiovascular-kidney-metabolic syndrome is a clinical entity requir...
The impact of socioeconomic crisis on cancer patient outcomes in Lebanon, 2018-2020 [0.03%]
2018至2020年经济危机对黎巴嫩癌症患者预后的影响
Joel Ladner,Joseph Saba,Anas Nofel et al.
Joel Ladner et al.
Aim: The goal of this study was to assess the impact of economic and social crisis on access to cancer care in Lebanon. Materials & methods: A cancer Drug Access Program in Lebanon was launched, covering 80-90% of treatment costs. The progr...
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide [0.03%]
黑人转移性雄激素敏感型前列腺癌患者使用阿帕鲁胺或恩杂鲁胺的深度前列腺特异性抗原反应比较研究
Benjamin H Lowentritt,Sabree Burbage,Ibrahim Khilfeh et al.
Benjamin H Lowentritt et al.
Aim: There is limited real-world evidence about prostate-specific antigen (PSA) response to androgen receptor pathway inhibitor treatment in Black patients with metastatic castration-sensitive prostate cancer (mCSPC). This study compared PS...
Effectiveness and safety of therapies for patients with opioid use disorder: a systematic review and network meta-analysis [0.03%]
阿片类药物使用障碍患者的治疗效果和安全性：系统评价和网络meta分析
Madhusudan Kabra,Tushar Srivastava,Raju Gautam et al.
Madhusudan Kabra et al.
Aim: Opioid use disorder (OUD) leads to significant morbidity and mortality. While opioid agonist therapies like transmucosal buprenorphine and methadone are effective, they face challenges such as poor adherence, diversion risk and subopti...
The importance and challenge of comparing stroke care, utilization and outcomes in Medicare Advantage and Fee-for-Service Medicare: a narrative review and vision for the future [0.03%]
比较医疗保险优势和按服务收费的医疗保险中的卒中护理、利用情况和结果的重要性与挑战：叙述性回顾及未来展望
Emily J Bian,Priyanka Menon,Kathleen A McManus et al.
Emily J Bian et al.
Stroke prevalence is highest in adults ≥65 years, the majority of whom are Medicare beneficiaries. Fee-for-Service Medicare (FFS) incentivizes utilization by paying for each service. Medicare Advantage (MA) uses capitated payments to reduc...